T. Rowe Price Health Sciences
100 East Pratt Street Baltimore MD 21202
Phone: 800-638-5660
| Category: |
Health |
| Fund Family: |
T. Rowe Price |
| Net Assets: |
2.16B |
| Year-to-Date Return: |
0.73% |
| Yield: |
0.00% |
| Morningstar Rating: |
 |
| Fund Inception Date: |
29-Dec-95 |
|
Kris H. Jenner
Lead Manager since
14-Jan-00 |
|
| Kris Jenner is a Vice President, Portfolio Manager, and Investment Analyst with T. Rowe Price. He joined the firm in June of 1997 and has five years of previous investment experience. He specializes in the coverage of the biotechnology and domestic pharmaceutical sectors of the health care industry. Kris earned a B.S. (Chemistry), summa cum laude from the University of Illinois, a D. Phil. from Oxford university/England, and a M.D. from the Johns Hopkins School of Medicine. |
| Min Initial Investment: |
$2,500 |
| Min Initial Investment, IRA: |
$1,000 |
| Min Initial Investment, AIP: |
$0 |
| Min Subsequent Investment: |
$100 |
| Min Subsequent Investment, IRA: |
$50 |
| Min Subsequent Investment, AIP: |
$50 |
|
|
|
| The investment seeks long-term capital appreciation. The fund normally invests at least 80% of assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. While it can invest in companies of any size, the fund invests the majority of assets in large- and mid-capitalization companies. |
| Last Dividend
|
N/A |
| Last Cap Gain
(15-Dec-08):
|
0.34 |
| Annual Holdings Turnover
|
47.40% |
| Average for Category:
|
152.72% |
|
| Expense |
PRHSX |
Category
Avg |
| Total Expense Ratio: |
0.86%
|
1.91% |
| Max 12b1 Fee: |
%
|
N/A |
| Max Front End Sales Load: |
%
|
5.33% |
| Max Deferred Sales Load: |
%
|
2.90% |
| 3 Yr Expense Projection*: |
$274 |
$763 |
| 5 Yr Expense Projection*: |
$477 |
$1,175 |
| 10 Yr Expense Projection*: |
$1,061 |
$2,275 |
|
|
Help
0.29 (1.12%) 
Profile
